Global Bio Similars/Subsequent Entry Biologic Market By Product Type (Monoclonal Antibodies, Interferon) And By End-Users/Application (Tumor, Diabetes) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

According to Apex Market Research the Bio Similars/Subsequent Entry Biologic market was valued at USD xx.xx million in 2019 and is anticipated to grow at a CAGR of xx% during the forecast period from 2020 to 2028. The report on Bio Similars/Subsequent Entry Biologic market delivers detailed analysis covering major regional trends, market dynamics, and offer country-level market value of Bio Similars/Subsequent Entry Biologic industry. Some of the major aspects considered during the course of research comprises definition of the product, classification of the product, industry structure, different participants in the Bio Similars/Subsequent Entry Biologic ecosystem, etc. The report comprises of market value and forecast for the period from 2020 to 2028, CAGR measured for individual segment and regional market, competitive landscape of key market players, and profiling of major providers participating in the Bio Similars/Subsequent Entry Biologic market.

The following manufacturers are covered in this report:
  • Sun Pharma
  • Synthon Pharmaceuticals
  • Teva Pharmaceutical Industries
  • LG Life Sciences
  • Celltrion Biocon
  • Hospira
  • Merck
  • Biogen idec
  • Genentech (Roche)
  • Pfizer
  • Celltrion
  • Biocon
  • Amgen
  • Samsung Biologics
  • Mylan
  • Dr. Reddy\'s Laboratories
  • Stada Arzneimittel AG
  • AbbVie
  • Sanofi-Aventis
  • Johnson & Johnson
  • Novo Nordisk
  • Eli Lilly
  • Novartis
  • 3sbio
  • Biotech
  • Gelgen
  • Innovent
  • Dong Bao
  • Ganlee

The report estimates on the Bio Similars/Subsequent Entry Biologic market economy trend, market numbers (Mn/Bn USD) and CAGR from the 2020-2028, considering 2019 as the base year. A global Bio Similars/Subsequent Entry Biologic market report consist of all leading industry players, Bio Similars/Subsequent Entry Biologic business sections, company profile, revenue supply by Bio Similars/Subsequent Entry Biologic industry sections, global Bio Similars/Subsequent Entry Biologic market trends, acquisitions and arrangements, contact info, recent development, geographic examination and even more using the assistance.

Since the onset of COVID-19 in December 2019, the governments of various countries declared lockdown and as result numerous economies around the world experienced severe economic downturn. Since early 2020, the Bio Similars/Subsequent Entry Biologic market witnessed the impact of COVID-19 The report objects to provide pre-COVID-19 state of the Bio Similars/Subsequent Entry Biologic market in years 2020 and 2019 and moreover it offers forecast for the Covid-19 period from 2020 to 2028.The report provides COVID-19 impact on Bio Similars/Subsequent Entry Biologic market, global analysis, different challenges or threats and opportunities for stakeholders involved in the Bio Similars/Subsequent Entry Biologic market.

Report Opportunity: Global Bio Similars/Subsequent Entry Biologic Market

This report delivers an analytical examination of the Bio Similars/Subsequent Entry Biologic market summarized in broad sections such as
  1. Bio Similars/Subsequent Entry Biologic Market Summary
  2. Key Commercial Growths in the Bio Similars/Subsequent Entry Biologic Industry
  3. Market Dynamics Affecting the Bio Similars/Subsequent Entry Biologic Industry
  4. Important Market Trends and Future Development Scenario of the Bio Similars/Subsequent Entry Biologic Market
  5. Bio Similars/Subsequent Entry Biologic Market Revenue and Forecast, by Type, 2018 – 2028
  6. Competitive Landscape of Bio Similars/Subsequent Entry Biologic Industry
  7. Positioning of Main Market Players in the Bio Similars/Subsequent Entry Biologic Industry
  8. Bio Similars/Subsequent Entry Biologic Market Revenue and Forecast, by Application, 2018 - 2028
  9. Bio Similars/Subsequent Entry Biologic Market Revenue and Forecast, by End-use, 2018 - 2028
  10. Bio Similars/Subsequent Entry Biologic Market Revenue and Forecast, by Geography, 2018 - 2028
Bio Similars/Subsequent Entry Biologic Market Segmentation:

The report provides detailed examination of the Bio Similars/Subsequent Entry Biologic market on the basis of various segments such as type, application and end-use industry. The Bio Similars/Subsequent Entry Biologic market is segmented as follows:

Bio Similars/Subsequent Entry Biologic Market, by Type:
  • Monoclonal Antibodies
  • Interferon
  • Erythropoietin
  • Insulin
  • Vaccines
  • Other
Bio Similars/Subsequent Entry Biologic Market, by Application:
  • Tumor
  • Diabetes
  • Cardiovascular
  • Hemophilia
  • Other
Geographic Coverage

The report on the Bio Similars/Subsequent Entry Biologic market delivers an in depth country-level cross-sectional analysis across different regions around the globe. The report comprises of complete market value and forecast for the following countries and regions:

North America Bio Similars/Subsequent Entry Biologic Market Revenue and Forecast
  • U.S.
  • Canada
Europe Bio Similars/Subsequent Entry Biologic Market Revenue and Forecast
  • UK
  • Germany
  • France
  • Rest of Europe
Asia Pacific Bio Similars/Subsequent Entry Biologic Market Revenue and Forecast
  • China
  • Japan
  • India
  • Rest of Asia Pacific
Latin America Bio Similars/Subsequent Entry Biologic Market Revenue and Forecast
  • Mexico
  • Brazil
  • Rest of Latin America
Middle East and Africa Bio Similars/Subsequent Entry Biologic Market Revenue and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Bio Similars/Subsequent Entry Biologic Market Snapshot
          2.1.1. Global Bio Similars/Subsequent Entry Biologic Market By Type,2019
               2.1.1.1.Monoclonal Antibodies
               2.1.1.2.Interferon
               2.1.1.3.Erythropoietin
               2.1.1.4.Insulin
               2.1.1.5.Vaccines
               2.1.1.6.Other
          2.1.2. Global Bio Similars/Subsequent Entry Biologic Market By Application,2019
               2.1.2.1.Tumor
               2.1.2.2.Diabetes
               2.1.2.3.Cardiovascular
               2.1.2.4.Hemophilia
               2.1.2.5.Other
          2.1.3. Global Bio Similars/Subsequent Entry Biologic Market By End-use,2019
          2.1.4. Global Bio Similars/Subsequent Entry Biologic Market By Geography,2019

3. Global Bio Similars/Subsequent Entry Biologic Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Bio Similars/Subsequent Entry Biologic Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Bio Similars/Subsequent Entry Biologic Market Size (US$), By Type, 2018 – 2028

5. Global Bio Similars/Subsequent Entry Biologic Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Bio Similars/Subsequent Entry Biologic Market Size (US$), By Application, 2018 – 2028

6. Global Bio Similars/Subsequent Entry Biologic Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Bio Similars/Subsequent Entry Biologic Market Size (US$), By End-use, 2018 – 2028

7. Global Bio Similars/Subsequent Entry Biologic Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Bio Similars/Subsequent Entry Biologic Market Analysis, 2018 – 2028 
          7.2.1. North America Bio Similars/Subsequent Entry Biologic Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Bio Similars/Subsequent Entry Biologic Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Bio Similars/Subsequent Entry Biologic Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Bio Similars/Subsequent Entry Biologic Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Bio Similars/Subsequent Entry Biologic Market Analysis, 2018 – 2028 
          7.3.1.  Europe Bio Similars/Subsequent Entry Biologic Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Bio Similars/Subsequent Entry Biologic Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Bio Similars/Subsequent Entry Biologic Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Bio Similars/Subsequent Entry Biologic Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Bio Similars/Subsequent Entry Biologic Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Bio Similars/Subsequent Entry Biologic Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Bio Similars/Subsequent Entry Biologic Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Bio Similars/Subsequent Entry Biologic Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Bio Similars/Subsequent Entry Biologic Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Bio Similars/Subsequent Entry Biologic Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Bio Similars/Subsequent Entry Biologic Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Bio Similars/Subsequent Entry Biologic Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Bio Similars/Subsequent Entry Biologic Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Bio Similars/Subsequent Entry Biologic Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Bio Similars/Subsequent Entry Biologic Market Analysis, 2018 – 2028 
          7.6.1.  MEA Bio Similars/Subsequent Entry Biologic Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Bio Similars/Subsequent Entry Biologic Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Bio Similars/Subsequent Entry Biologic Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Bio Similars/Subsequent Entry Biologic Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Bio Similars/Subsequent Entry Biologic Providers
        8.4.1 Sun Pharma
                8.1.1 Business Description
                8.1.2 Sun Pharma Geographic Operations
                8.1.3 Sun Pharma Financial Information
                8.1.4 Sun Pharma Product Positions/Portfolio
                8.1.5 Sun Pharma Key Developments
        8.4.2 Synthon Pharmaceuticals
                8.2.1 Business Description
                8.2.2 Synthon Pharmaceuticals Geographic Operations
                8.2.3 Synthon Pharmaceuticals Financial Information
                8.2.4 Synthon Pharmaceuticals Product Positions/Portfolio
                8.2.5 Synthon Pharmaceuticals Key Developments
        8.4.3 Teva Pharmaceutical Industries
                8.3.1 Business Description
                8.3.2 Teva Pharmaceutical Industries Geographic Operations
                8.3.3 Teva Pharmaceutical Industries Financial Information
                8.3.4 Teva Pharmaceutical Industries Product Positions/Portfolio
                8.3.5 Teva Pharmaceutical Industries Key Developments
        8.4.4 LG Life Sciences
                8.4.1 Business Description
                8.4.2 LG Life Sciences Geographic Operations
                8.4.3 LG Life Sciences Financial Information
                8.4.4 LG Life Sciences Product Positions/Portfolio
                8.4.5 LG Life Sciences Key Developments
        8.4.5 Celltrion Biocon
                8.5.1 Business Description
                8.5.2 Celltrion Biocon Geographic Operations
                8.5.3 Celltrion Biocon Financial Information
                8.5.4 Celltrion Biocon Product Positions/Portfolio
                8.5.5 Celltrion Biocon Key Developments
        8.4.6 Hospira
                8.6.1 Business Description
                8.6.2 Hospira Geographic Operations
                8.6.3 Hospira Financial Information
                8.6.4 Hospira Product Positions/Portfolio
                8.6.5 Hospira Key Developments
        8.4.7 Merck
                8.7.1 Business Description
                8.7.2 Merck Geographic Operations
                8.7.3 Merck Financial Information
                8.7.4 Merck Product Positions/Portfolio
                8.7.5 Merck Key Developments
        8.4.8 Biogen idec
                8.8.1 Business Description
                8.8.2 Biogen idec Geographic Operations
                8.8.3 Biogen idec Financial Information
                8.8.4 Biogen idec Product Positions/Portfolio
                8.8.5 Biogen idec Key Developments
        8.4.9 Genentech (Roche)
                8.9.1 Business Description
                8.9.2 Genentech (Roche) Geographic Operations
                8.9.3 Genentech (Roche) Financial Information
                8.9.4 Genentech (Roche) Product Positions/Portfolio
                8.9.5 Genentech (Roche) Key Developments
        8.4.10 Pfizer
                8.10.1 Business Description
                8.10.2 Pfizer Geographic Operations
                8.10.3 Pfizer Financial Information
                8.10.4 Pfizer Product Positions/Portfolio
                8.10.5 Pfizer Key Developments
        8.4.11 Celltrion
                8.11.1 Business Description
                8.11.2 Celltrion Geographic Operations
                8.11.3 Celltrion Financial Information
                8.11.4 Celltrion Product Positions/Portfolio
                8.11.5 Celltrion Key Developments
        8.4.12 Biocon
                8.12.1 Business Description
                8.12.2 Biocon Geographic Operations
                8.12.3 Biocon Financial Information
                8.12.4 Biocon Product Positions/Portfolio
                8.12.5 Biocon Key Developments
        8.4.13 Amgen
                8.13.1 Business Description
                8.13.2 Amgen Geographic Operations
                8.13.3 Amgen Financial Information
                8.13.4 Amgen Product Positions/Portfolio
                8.13.5 Amgen Key Developments
        8.4.14 Samsung Biologics
                8.14.1 Business Description
                8.14.2 Samsung Biologics Geographic Operations
                8.14.3 Samsung Biologics Financial Information
                8.14.4 Samsung Biologics Product Positions/Portfolio
                8.14.5 Samsung Biologics Key Developments
        8.4.15 Mylan
                8.15.1 Business Description
                8.15.2 Mylan Geographic Operations
                8.15.3 Mylan Financial Information
                8.15.4 Mylan Product Positions/Portfolio
                8.15.5 Mylan Key Developments
        8.4.16 Dr. Reddy\'s Laboratories
                8.16.1 Business Description
                8.16.2 Dr. Reddy\'s Laboratories Geographic Operations
                8.16.3 Dr. Reddy\'s Laboratories Financial Information
                8.16.4 Dr. Reddy\'s Laboratories Product Positions/Portfolio
                8.16.5 Dr. Reddy\'s Laboratories Key Developments
        8.4.17 Stada Arzneimittel AG
                8.17.1 Business Description
                8.17.2 Stada Arzneimittel AG Geographic Operations
                8.17.3 Stada Arzneimittel AG Financial Information
                8.17.4 Stada Arzneimittel AG Product Positions/Portfolio
                8.17.5 Stada Arzneimittel AG Key Developments
        8.4.18 AbbVie
                8.18.1 Business Description
                8.18.2 AbbVie Geographic Operations
                8.18.3 AbbVie Financial Information
                8.18.4 AbbVie Product Positions/Portfolio
                8.18.5 AbbVie Key Developments
        8.4.19 Sanofi-Aventis
                8.19.1 Business Description
                8.19.2 Sanofi-Aventis Geographic Operations
                8.19.3 Sanofi-Aventis Financial Information
                8.19.4 Sanofi-Aventis Product Positions/Portfolio
                8.19.5 Sanofi-Aventis Key Developments
        8.4.20 Johnson & Johnson
                8.20.1 Business Description
                8.20.2 Johnson & Johnson Geographic Operations
                8.20.3 Johnson & Johnson Financial Information
                8.20.4 Johnson & Johnson Product Positions/Portfolio
                8.20.5 Johnson & Johnson Key Developments
        8.4.21 Novo Nordisk
                8.21.1 Business Description
                8.21.2 Novo Nordisk Geographic Operations
                8.21.3 Novo Nordisk Financial Information
                8.21.4 Novo Nordisk Product Positions/Portfolio
                8.21.5 Novo Nordisk Key Developments
        8.4.22 Eli Lilly
                8.22.1 Business Description
                8.22.2 Eli Lilly Geographic Operations
                8.22.3 Eli Lilly Financial Information
                8.22.4 Eli Lilly Product Positions/Portfolio
                8.22.5 Eli Lilly Key Developments
        8.4.23 Novartis
                8.23.1 Business Description
                8.23.2 Novartis Geographic Operations
                8.23.3 Novartis Financial Information
                8.23.4 Novartis Product Positions/Portfolio
                8.23.5 Novartis Key Developments
        8.4.24 3sbio
                8.24.1 Business Description
                8.24.2 3sbio Geographic Operations
                8.24.3 3sbio Financial Information
                8.24.4 3sbio Product Positions/Portfolio
                8.24.5 3sbio Key Developments
        8.4.25 Biotech
                8.25.1 Business Description
                8.25.2 Biotech Geographic Operations
                8.25.3
3480

1652

OUR CLIENT